Skip to main content
. 2014 Oct 7;7:1851–1867. doi: 10.2147/OTT.S68386

Table 1.

Baseline characteristics of included randomized controlled trials in the meta-analysis

Cancer type Reference Trial phase Treatment arms Median age/years Median TX (duration/monthsa) Median PFS (monthsa) Median OS (monthsa) N of patients for analysis N of deaths due to study drug Jadad score
NSCLC Paz-Ares et al21 III Sorafenib 400 mg BID + GP 60 4.0 6.0 12.4 385 5 5
Placebo + GP 58 4.2 5.5 12.5 384 2
Scagliotti et al34 III Sorafenib 400 mg BID + TC 62 3.9 4.6 10.7 436 13 4
Placebo + TC 63 4.2 5.4 10.6 459 4
Scagliotti et al35 III Sunitinib 37.5 mg/day + erlotinib 61 4.3 3.6 9.0 473 4 5
Placebo + erlotinib 61 4.3 2.0 8.5 477 4
Groen et al30 II Sunitinib 37.5 mg/day + erlotinib 59 2.0 2.8 8.2 64 1 5
Placebo + erlotinib 61 2.8 2.0 7.6 64 0
Heist et al31 II Sunitinib 37.5 mg/day + PMX NR NR 3.7 6.7 41 2 2
Sunitinib 37.5 mg/day NR NR 3.3 8.0 47 1
PMX NR NR 4.9 10.5 42 0
Heymach et al32 II Vandetanib 100 mg/day + DTX 61 NR 4.4 13.1 42 0 2
Vandetanib 300 mg/day + DTX 60 NR 2.8 7.9 44 0
Placebo + DTX 58 NR 4.0 13.4 41 0
Ahn et al29 II Vandetanib 300 mg/day 61 2.0 2.7 15.6 75 0 2
Placebo 60.5 1.8 1.7 20.8 42 0
Heymach et al33 II Vandetanib 300 mg/day + TC 60 NR 5.6 10.2* 56 2 2
Placebo + TC 59 NR 5.4 12.6* 52 0
Vandetanib 300 mg/day 73 NR 2.7 10.2* 73 0
CRC Tabernero et al12 II Sorafenib 400 mg BID + mFOLFOX6 59.2 7.1 9.1 17.6 97 2 3
Placebo + mFOLFOX6 60.3 7.9 8.7 18.1 101 1
Carrato et al14 III Sunitinib 37.5 mg/day + FOLFIRI 59 NR 7.8 20.3 384 12 3
Placebo + FOLFIRI 58 NR 8.4 19.8 379 4
Breast cancer Baselga et al16 II Sorafenib 400 mg BID + Cap 55.1 7.9 6.4 22.9 112 0 5
Placebo + Cap 54.4 5.3 4.1 20.9 112 2
Schwartzberg et al39 II Sorafenib 400 mg BID + Gem/Cap 53.5 NR 3.4 13.4 79 1 3
Placebo + Gem/Cap 54.2 NR 2.7 11.4 77 0
Gradishar et al18 II Sorafenib 400 mg BID + PTX 50.6 6.4 6.9 16.8 115 2 5
Placebo + PTX 53.1 6.8 5.6 17.4 118 0
Barrios et al36 III Sunitinib 37.5 mg daily 53 2.2 2.8 15.3 238 5 3
Cap 53 2.2 4.2 24.6 240 2
Bergh et al22 III Sunitinib 37.5 mg/day + DTX 54 6.1 8.6 24.8 295 2 2
Placebo + DTX 56 4.2 8.3 25.5 293 0
Johnston et al38 II Pazopanib 400 mg/day + lapatinib 50 NR NR NR 76 0 2
Lapatinib 54 NR NR NR 73 0
Boér et al37 II Vandetanib 100 mg/day + DTX 54 4.8 8.2 NR 33 0 3
Placebo + DTX 57 4.0 5.6 NR 29 1
Rugo et al24 III Axitinib 5 mg BID + DTX 55 NR 8.1* NR 111 1 3
Placebo + DTX 56 NR 7.1* NR 56 0
RCC Escudier et al5 III Sorafenib 400 mg BID 58 5.4 5.5 19.3 451 2 4
Placebo 59 2.8 2.8 15.9 451 1
Hutson et al20 III Sorafenib 400 mg BID 61 3.6 3.9 16.6 249 2 2
Temsirolimus 25 mg/day 60 4.4 4.3 12.3 252 3
Motzer et al40 III Sunitinib 50 mg for 4 weeks every 6 weeks 62 11.0 11.0 26.4 375 1 3
Interferon 59 4.0 5.0 21.8 360 2
Sternberg et al41 III Pazopanib 800 mg/day 59 7.4 9.2 Not reached 290 4 5
Placebo 60 3.8 4.2 Not reached 145 0
HCC Cheng et al42 III Sorafenib 400 mg BID 51 NR 2.8* 6.5 149 0 5
Placebo 52 NR 1.4* 4.2 75 0
Kudo et al43 III Sorafenib 400 mg BID 69 4.0 5.4* 29.7 229 0 3
Placebo 70 4.7 3.1* Not reached 227 0
Pancreatic cancer Gonçalves et al17 III Sorafenib 400 mg BID + Gem 61 3.7 5.7 9.2 50 1 3
Placebo + Gem 64 5.6 3.8 8.0 52 0
Reni et al44 II Sunitinib 37.5 mg/day 61 3.0 3.2 10.6 28 0 2
Observation 65 NR 2.0 9.2 27 0
Prostate cancer Horti et al45 II Vandetanib 100 mg/day + DTX + prednisolone 67 4.2 NR NR 43 0 3
Placebo + DTX + prednisolone 67 8.4 NR NR 43 2
Michaelson et al11 III Sunitinib 37.5 mg/day + prednisone 69 3.3 5.6 13.1 581 12 3
Placebo + prednisone 68 3.2 4.1 11.8 285 1
Melanoma Flaherty et al13 III Sorafenib 400 mg BID + TC 61 NR 4.9 11.1 393 9 3
Placebo + TC 59 NR 4.2 11.3 397 7
Hauschild et al46 III Sorafenib 400 mg BID + TC 56 4.1 4.1 9.8 134 4 5
Placebo + TC 55.1 4.0 4.2 9.8 134 0
McDermott et al47 II Sorafenib 400 mg BID + dacarbazine 55 4.5 4.9 10.6 50 0 5
Placebo + dacarbazine 60 2.8 2.7 12.0 51 0
GIST Demetri et al23 III Sunitinib 50 mg for 4 weeks every 6 weeks 57 1.9 5.3 17.0 228 4 3
Placebo 55 0.9 1.4 15.1 114 2
Demetri et al25 III Regorafenib 160 mg/day 60 5.3 4.8 Not reached 132 2 5
Placebo 61 1.6 0.9 Not reached 66 1
Ovarian cancer Herzog et al19 II Sorafenib 400 mg BID 56.9 4.1 12.7 Not reached 123 0 3
Placebo 54.4 12.1 15.7 Not reached 123 0
PNET Raymond et al6 III Sunitinib 37.5 mg daily 56 4.6 11.4 Not reached 83 1 3
Placebo 47 3.7 5.5 Not reached 82 1
STS van der Graaf et al3 III Pazopanib 800 mg/day 56.7 3.8 4.6 11.9 239 1 5
Placebo 51.9 1.9 1.6 10.4 123 0
Thyroid cancer Leboulleux et al15 II Vandetanib 300 mg/day 63 6.4 11.1 Not reached 73 2 5
Placebo 64 5.9 5.9 Not reached 72 1
Elisei et al4 III Cabozantinib 140 mg/day 55 6.8 11.2 NR 214 9 3
Placebo 55 3.5 4 NR 109 2
SCLC Arnold et al48 II Vandetanib 300 mg/day 56.9 1.7 2.7 10.6 52 0 4
Placebo 62.4 2.8 2.8 11.9 53 0
Urothelial cancer Choueiri et al49 II Vandetanib 100 mg/day + DTX NR 1.4 2.6 5.9 70 1 5
Placebo + DTX NR 1.6 7.0 72 0
SCCHN Limaye et al50 II Vandetanib 100 mg/day + DTX 60 2.1 2.1 5.6 15 0 3
Placebo + DTX 56 1.4 0.7 6.3 14 2

Notes:

a

When durations were reported as weeks, we converted them to months (1 week =7 days; 1 month =30 days).

*

Reported as time to progression.

Abbreviations: TX, treatment; PFS, progression-free survival; OS, overall survival; N, number; NSCLC, nonsmall-cell lung cancer; BID, twice daily; GP, gemcitabine + cisplatin; TC, paclitaxel + carboplatin; PMX, pemetrexed; NR, not reported; CRC, colorectal cancer; mFOLFOX6, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; Cap, capecitabine; Gem, gemcitabine; PTX, paclitaxel; DTX, docetaxel; RCC, renal cell cancer; HCC, hepatocellular cancer; GIST, gastrointestinal stromal cancer; PNET, pancreatic neuroendocrine cancer; STS, soft-tissue sarcoma; SCLC, small-cell lung cancer; SCCHN, squamous cell cancer of the head and neck.